The present invention relates to the use of esters and/or ethers of 3-methyl-pentane-diol and unsaturated derivates thereof as aroma chemicals, to aroma chemical compositions comprising at least one ester of 3-methyl-pentan-diol and/or unsaturated derivates thereof and/or at least one ether of 3-methyl-pentan-diol and/or unsaturated derivates thereof and to a method for preparing an aroma chemical composition, in particular a fragranced composition, specifically a fragranced ready-to-use composition, which comprises incorporating at least one ester of 3-methyl-pentane-diol and/or one or more unsaturated derivates thereof and/or at least one ether 3-methyl-pentane-diol and/or one or more unsaturated derivates thereof into a composition, in particular into a ready-to-use composition. The present invention further relates to specific ethers of 3-methyl-pentane-diol and unsaturated derivates thereof and to specific esters of 3-methyl-pentane-diol, to specific mixtures of such compounds and to unsaturated derivates thereof and a method for their preparation.

The present invention relates to the use of esters and/or ethers of 3-methyl-pentane-diol and unsaturated derivates thereof as aroma chemicals, to aroma chemical compositions comprising at least one ester of 3-methyl-pentan-diol and/or unsaturated derivates thereof and/or at least one ether of 3-methyl-pentan-diol and/or unsaturated derivates thereof and to a method for preparing an aroma chemical composition, in particular a fragranced composition, specifically a fragranced ready-to-use composition, which comprises incorporating at least one ester of 3-methyl-pentane-diol and/or one or more unsaturated derivates thereof and/or at least one ether 3-methyl-pentane-diol and/or one or more unsaturated derivates thereof into a composition, in particular into a ready-to-use composition. The present invention further relates to specific ethers of 3-methyl-pentane-diol and unsaturated derivates thereof and to specific esters of 3-methyl-pentane-diol, to specific mixtures of such compounds and to unsaturated derivates thereof and a method for their preparation.

Gracilin A congeners and methods for their use as immunosuppressive and neuroprotective agents.

Disclosed herein is a process for chemically synthesizing of hydroquinone derivatives, especially for hydroquinone derivatives with heptadecatrienyl side chain, which is synthesized via a Wittig reaction of 2-(10′-oxononyl)-1,4-diacetoxyl benzene and (3E, 5Z)-3,5-heptadien-1-triphenylphosphonium iodide and then deacetylation. In addition, the product is solid powder.

Disclosed herein is a process for chemically synthesizing of hydroquinone derivatives, especially for hydroquinone derivatives with heptadecatrienyl side chain, which is synthesized via a Wittig reaction of 2-(10′-oxononyl)-1,4-diacetoxyl benzene and (3E, 5Z)-3,5-heptadien-1-triphenylphosphonium iodide and then deacetylation. In addition, the product is solid powder.

The invention relates to a method for preparation of diesters from anhydrides of carboxylic acids.

The invention relates to a method for preparation of diesters from anhydrides of carboxylic acids.

The ketogenic diet (KD) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mM) without need for dietary restriction. The effects of ketogenic agents were tested on blood glucose, ketones, and lipids with a 28-day dose escalation study in male Sprague-Dawley rats: R,S-1,3-Butandiol (BD), acetoacetate ketone ester (KE), and control (H.sub.2O) (n≥8). Days 1-28, rats received a daily 5g/kg intragastric gavage, based on previous toxicology studies. Once weekly, whole blood samples (10 μl) were acquired for analysis of glucose and βHB at 0, 0.5, 1, 4, 8, and 12 hours after test substance administration, or until βHB returned to baseline. At day 1 and 28, 10 μL of whole blood were collected to measure triglycerides, total cholesterol, and HDL concentration. Significant elevation of blood ketone was observed with a significant inverse relationship with blood glucose for the duration of the experiment. There were no significant changes in the lipid panel for any of the substances. There were significant reductions in body weight when animals were treated with either BD or KE as compared to control.

The ketogenic diet (KD) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mM) without need for dietary restriction. The effects of ketogenic agents were tested on blood glucose, ketones, and lipids with a 28-day dose escalation study in male Sprague-Dawley rats: R,S-1,3-Butandiol (BD), acetoacetate ketone ester (KE), and control (H.sub.2O) (n≥8). Days 1-28, rats received a daily 5g/kg intragastric gavage, based on previous toxicology studies. Once weekly, whole blood samples (10 μl) were acquired for analysis of glucose and βHB at 0, 0.5, 1, 4, 8, and 12 hours after test substance administration, or until βHB returned to baseline. At day 1 and 28, 10 μL of whole blood were collected to measure triglycerides, total cholesterol, and HDL concentration. Significant elevation of blood ketone was observed with a significant inverse relationship with blood glucose for the duration of the experiment. There were no significant changes in the lipid panel for any of the substances. There were significant reductions in body weight when animals were treated with either BD or KE as compared to control.

The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.